Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
National Institutes of Health · Department of Health and Human Services
At a glance
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) is an open federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due January 7, 2028. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.242 (Mental Health Research Grants) and 1 other listing.
Summary assembled from the official notice's fields. The official notice governs.
Key facts
- Nov 22, 2024Posted
- Jan 7, 2028Application deadlinenext date
- Feb 12, 2028Archived
- Posted
- Nov 22, 2024
- Close date
- Jan 7, 2028
- Archive date
- Feb 12, 2028
- Award floor
- Not specified
- Award ceiling
- Not specified
- Est. total funding
- Not specified
- Expected awards
- Not specified
- Cost sharing
- Not required
- Funding instrument
- Grant
- Opportunity category
- Discretionary
Typical awards for this program (SAM.gov listing for ALN 93.242, not this notice): FY 2023 range: $1 to $17,379,729 Average Cost: $508,267
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public colleges & universities
- Federally recognized tribal governments
- Public & Indian housing authorities
- Native American tribal organizations
- 501(c)(3) nonprofits
- Nonprofits without 501(c)(3) status
- Private colleges & universities
- For-profit organizations (not small businesses)
- Small businesses
- Others (see notice)
Additional information on eligibility (from the notice)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
A quick check against the listed applicant types — other requirements in the notice still apply.
Based on the published notice. Review the official notice for complete eligibility requirements.
What it funds
Official synopsis as published by the agency, formatted for readability.
The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Full announcement & documents
The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.
How to apply
0 of 8 done · progress saved in this browser
Assistance Listings
What is an ALN?Reported obligations under ALN 93.242
Historical data · not a predictionAgency contact (as published)
National Institutes of Health
grantsinfo@nih.gov
301-402-2541
Quick answers
When is the deadline for “Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)”?
According to the official notice, applications are due January 7, 2028. Confirm the deadline and submission time on Grants.gov before applying.
Who is eligible to apply for “Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)”?
The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.
How do I apply for “Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)”?
Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-25-281), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.
Related open opportunities
Matched on shared Assistance Listings, agency, categories and eligible applicant types.
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Nov 18, 2026
- Who can apply
- State governments, County governments, City or township governments and 12 more
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Dec 3, 2026
- Who can apply
- Others (see notice)
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
National Institutes of Health- Award range
- Amount not specified
- Closes
- May 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- May 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- May 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jan 7, 2028
- Who can apply
- State governments, County governments, City or township governments and 12 more